Revolution Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Revolution Medicines
RVMD Stock  USD 57.50  0.75  1.32%   
Revolution Medicines financial statements provide useful quarterly and yearly information to potential Revolution Medicines investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Revolution Medicines financial statements helps investors assess Revolution Medicines' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Revolution Medicines' valuation are summarized below:
Gross Profit
-217.7 M
Market Capitalization
9.5 B
Enterprise Value Revenue
10.9 K
Revenue
742 K
Earnings Share
(3.66)
There are over one hundred nineteen available trending fundamental ratios for Revolution Medicines, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Revolution Medicines' recent performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 3.4 B, whereas Enterprise Value is forecasted to decline to about 1.4 B.

Revolution Medicines Total Revenue

11 Million

Check Revolution Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revolution Medicines' main balance sheet or income statement drivers, such as Net Interest Income of 49.5 M, Interest Income of 49.9 M or Depreciation And Amortization of 6.5 M, as well as many indicators such as Price To Sales Ratio of 294, Dividend Yield of 0.0 or PTB Ratio of 1.69. Revolution financial statements analysis is a perfect complement when working with Revolution Medicines Valuation or Volatility modules.
  
Check out the analysis of Revolution Medicines Correlation against competitors.
For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.

Revolution Medicines Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.2 B2.1 B457 M
Slightly volatile
Other Current Liabilities70.7 M67.3 M17.2 M
Slightly volatile
Total Current Liabilities151 M143.9 M37.2 M
Slightly volatile
Total Stockholder Equity1.9 B1.8 B386.1 M
Slightly volatile
Other Liabilities6.3 M6.6 M9.6 M
Slightly volatile
Property Plant And Equipment Net105 M100 M29.5 M
Slightly volatile
Accounts Payable64.9 M61.8 M14.5 M
Slightly volatile
Cash731 M696.1 M130.7 M
Slightly volatile
Non Current Assets Total123.5 M182.4 M63.2 M
Slightly volatile
Other Assets0.951.0994.3 K
Slightly volatile
Cash And Short Term Investments1.9 B1.9 B381.8 M
Slightly volatile
Common Stock Shares Outstanding73.1 M113.1 M52.9 M
Slightly volatile
Liabilities And Stockholders Equity2.2 B2.1 B457 M
Slightly volatile
Non Current Liabilities Total61.2 M91.7 M31.4 M
Slightly volatile
Capital Surpluse1.3 B1.2 B356.5 M
Slightly volatile
Other Current Assets26.3 M25.1 M5.5 M
Slightly volatile
Other Stockholder Equity3.1 B3 B632.9 M
Slightly volatile
Total Liabilities247.3 M235.5 M70.9 M
Slightly volatile
Property Plant And Equipment Gross123.6 M117.7 M33.6 M
Slightly volatile
Total Current Assets2 B1.9 B389.3 M
Slightly volatile
Non Current Liabilities Other1.4 M1.5 M2.9 M
Pretty Stable
Net Working Capital1.8 B1.7 B352.1 M
Slightly volatile
Common Stock8.1 K16 K4.4 K
Slightly volatile
Property Plant Equipment89 M84.8 M25.6 M
Slightly volatile
Short and Long Term Debt Total46.2 M87.9 M20 M
Slightly volatile
Net Receivables1.2 M1.3 M6.3 M
Slightly volatile
Common Stock Total Equity6.6 K9.2 K4.9 K
Slightly volatile
Long Term Debt Total136.8 K153.9 K167.6 K
Slightly volatile
Capital Stock15.2 K16 K20.3 M
Pretty Stable
Short Term Debt8.2 M14.7 M3.6 M
Slightly volatile
Intangible Assets48.3 M57.7 M61 M
Slightly volatile
Short Term Investments1.2 B1.2 B314.7 M
Slightly volatile
Deferred Long Term Liabilities513 K540 K2 M
Pretty Stable

Revolution Medicines Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income49.5 M47.2 M7.4 M
Slightly volatile
Interest Income49.9 M47.5 M7.6 M
Slightly volatile
Depreciation And Amortization6.5 M9.3 M3.7 M
Slightly volatile
Interest Expense287.9 K303 K758.4 K
Slightly volatile
Selling General Administrative79.4 M75.6 M20.4 M
Slightly volatile
Other Operating Expenses523.7 M498.8 M140.1 M
Slightly volatile
Research Development444.3 M423.1 M119.7 M
Slightly volatile
Cost Of Revenue431.8 M411.2 M89.8 M
Slightly volatile
Total Operating Expenses523.7 M498.8 M140.1 M
Slightly volatile
Reconciled Depreciation6.1 M9.3 M3.6 M
Slightly volatile
Non Operating Income Net Other1.3 M836.1 K1.9 M
Slightly volatile
Selling And Marketing Expenses2.6 M2.9 M3.1 M
Slightly volatile

Revolution Medicines Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation64.9 M61.8 M12.8 M
Slightly volatile
Begin Period Cash Flow171.3 M163.1 M50.1 M
Slightly volatile
Depreciation6.1 M9.3 M3.6 M
Slightly volatile
Capital Expenditures5.3 M7.7 M3.3 M
Slightly volatile
Total Cash From Financing Activities1.3 B1.2 B258.6 M
Slightly volatile
End Period Cash Flow734.1 M699.2 M131.4 M
Slightly volatile
Change To Netincome34 M32.4 M9 M
Slightly volatile
Issuance Of Capital Stock285.2 M385.8 M155 M
Slightly volatile
Change Receivables396.7 K417.6 K1.8 M
Slightly volatile
Cash And Cash Equivalents Changes4.2 M4.4 M66.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio29428083.7993
Slightly volatile
PTB Ratio1.691.777127
Slightly volatile
Days Sales Outstanding75.4639.5259103
Slightly volatile
Book Value Per Share16.9516.13964.2147
Slightly volatile
Stock Based Compensation To Revenue5.65.33440.8782
Slightly volatile
Capex To Depreciation0.980.83031.1
Slightly volatile
PB Ratio1.691.777127
Slightly volatile
EV To Sales23922874.1439
Slightly volatile
Payables Turnover6.996.65572.422
Slightly volatile
Sales General And Administrative To Revenue6.866.53031.368
Slightly volatile
Research And Ddevelopement To Revenue38.3736.54097.7423
Slightly volatile
Capex To Revenue0.70.66740.179
Slightly volatile
Cash Per Share17.1916.37614.1393
Slightly volatile
Days Payables Outstanding52.154.84734
Slightly volatile
Intangibles To Total Assets0.03330.03510.3226
Slightly volatile
Net Debt To EBITDA1.481.41250.5832
Slightly volatile
Current Ratio8.1113.06415.8521
Slightly volatile
Tangible Book Value Per Share16.2815.50023.6943
Slightly volatile
Receivables Turnover4.939.23444.2663
Slightly volatile
Graham Number39.2937.422811.0704
Slightly volatile
Shareholders Equity Per Share16.9516.13964.2147
Slightly volatile
Debt To Equity0.00380.0040.0094
Slightly volatile
Capex Per Share0.0530.06830.0546
Slightly volatile
Revenue Per Share0.09720.10230.5008
Slightly volatile
Interest Debt Per Share0.07120.06780.0225
Slightly volatile
Debt To Assets0.00340.00360.0078
Slightly volatile
Price Book Value Ratio1.691.777127
Slightly volatile
Days Of Payables Outstanding52.154.84734
Slightly volatile
Ebt Per Ebit1.080.90290.9947
Pretty Stable
Company Equity Multiplier1.771.1292.4223
Slightly volatile
Total Debt To Capitalization0.00380.0040.0093
Slightly volatile
Debt Equity Ratio0.00380.0040.0094
Slightly volatile
Quick Ratio8.1613.06415.8859
Slightly volatile
Net Income Per E B T0.780.9920.9258
Very volatile
Cash Ratio5.084.83942.1793
Slightly volatile
Days Of Sales Outstanding75.4639.5259103
Slightly volatile
Price To Book Ratio1.691.777127
Slightly volatile
Fixed Asset Turnover0.110.11582.3808
Slightly volatile
Debt Ratio0.00340.00360.0078
Slightly volatile
Price Sales Ratio29428083.7993
Slightly volatile
Asset Turnover0.00530.00560.0974
Slightly volatile
Price Fair Value1.691.777127
Slightly volatile

Revolution Medicines Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.4 B3.2 B1.6 B
Slightly volatile
Enterprise Value1.4 B2.6 B1.4 B
Slightly volatile

Revolution Fundamental Market Drivers

Cash And Short Term Investments1.9 B

Revolution Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Revolution Medicines Financial Statements

Revolution Medicines stakeholders use historical fundamental indicators, such as Revolution Medicines' revenue or net income, to determine how well the company is positioned to perform in the future. Although Revolution Medicines investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revolution Medicines' assets and liabilities are reflected in the revenues and expenses on Revolution Medicines' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revolution Medicines. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-54.6 M-51.8 M
Total Revenue11.6 M11 M
Cost Of Revenue411.2 M431.8 M
Stock Based Compensation To Revenue 5.33  5.60 
Sales General And Administrative To Revenue 6.53  6.86 
Research And Ddevelopement To Revenue 36.54  38.37 
Capex To Revenue 0.67  0.70 
Revenue Per Share 0.10  0.10 
Ebit Per Revenue(42.07)(39.97)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:
How To Invest In Revolution
Details
Is Revolution Stock a good investment?
Details
What is Revolution Medicines' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Revolution Medicines Correlation against competitors.
For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.66)
Revenue Per Share
0.005
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.29)
Return On Equity
(0.47)
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY